Progenitor is developing a unique platform technology consisting of pre-characterized, GMPgrade iPSC cell lines designed to accelerate the entry of cell therapy products into the clinical marketplace. The platform will enable the creation of safe immune-compatible allogenic Off-The-Shelf (OTS) cell therapies.

Progenitor’s platform employs a fully scalable workflow centered around master cell lines engineered for universal immune-compatibility. Cells are further functionalized by site-specific insertion of bacterial integrase receiver sites enabling safe and reliable insertion of new DNA constructs into defined genomic loci with low risk for off-target events. Progenitor will use this approach to produce immune-compatible iPSC Receiver Cells that can be differentiated into many different mature cell types for use in cell therapy applications.